Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System
Retrieved on:
Monday, February 24, 2020
Infectious diseases, Biotechnology, Pharmaceutical, Health, Articles, Life sciences, Health, Adjuvants, Biotechnology, Vaccine, Polyclonal antibodies, Biomanufacturing, AS04, Influenza research, Clover Biopharmaceuticals, Trimer-Tag© Technology, Wuhan Coronavirus SARS-CoV-2, S-Trimer COVID-19 Vaccine, GSK
GSK will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies.
Key Points:
- GSK will provide Clover with its pandemic adjuvant system for further evaluation of S-Trimer in preclinical studies.
- Having one of the largest in-house, commercial-scale cGMP biomanufacturing capabilities in China, Clover could potentially rapidly scale-up and produce large-quantities of a new coronavirus vaccine.
- GSK is a leader in the development of innovative vaccines using different adjuvant systems.
- At Clover we look forward to evaluating the combination of GSKs pandemic adjuvant system and our S-Trimer as a vaccine candidate.